Author Affiliation: Department of Internal
Medicine, University of Vienna, Medical School, Vienna, Austria.
Cardiovascular risk prediction by noninvasive laboratory testing in
the general population is becoming increasingly recognized as an important
health care issue. During the last decade, a variety of novel potentially
powerful prognostic biomarkers emerged, which may yield prognostic information
even in individuals without evidence of prevalent disease. Among the panel
of promising parameters, the role of natriuretic peptides and inflammatory
markers has been extensively studied in various populations and clinical settings.
Natriuretic peptides have been shown to predict outcome of patients with heart
failure, coronary artery, and valvular heart disease.1- 4 However,
unlike studies examining C-reactive protein (CRP),5- 7 investigations
of natriuretic peptides in predicting future cardiovascular events have not
been conducted in population-based samples, and comparative analyses including
a variety of prognostic biomarkers are scarce.5,8
Schillinger M. Cardiovascular Risk Stratification in Older PatientsRole of Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels. JAMA. 2005;293(13):1667-1669. doi:10.1001/jama.293.13.1667